Antiparasitic Drugs Global Market Growth Opportunities, Emerging Trends, Industry Analysis And Global Forecast 2024 To 2033 | Zoetis Inc., Eisai Co. Ltd., Covetrus Inc., IDEXX Laboratories Inc., Dr. Reddy's Laboratories

The antiparasitic drugs market size has grown strongly in recent years. It will grow from $22.47 billion in 2023 to $24.06 billion in 2024 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to prevalence of parasitic infections, resistance to existing treatments, global health initiatives, .

The antiparasitic drugs market size is expected to see strong growth in the next few years. It will grow to $31.19 billion in 2028 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to emerging parasitic threats, climate change and vector-borne diseases, increased emphasis on global health security, access to healthcare. Major trends in the forecast period include advances in drug development, targeted therapies, combination therapies, public-private partnerships, telemedicine and remote diagnosis.

Market Overview -
Antiparasitic drugs are medications used to treat infections caused by various parasites that can infect humans, animals, or plants. Parasites are organisms that live on or within a host organism and derive their nutrients from it, often causing harm to the host in the process. Antiparasitic drugs target these parasites to either kill them or inhibit their growth.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=12927&type=smp

Rising Incidence Of Vector-Borne Diseases Sparks Growth In The Antiparasitic Drugs Market
The increasing incidence of vector-borne diseases is expected to propel the growth of the antiparasitic drugs market going forward. Vector-borne diseases refer to infectious diseases transmitted to humans or other animals through the bite of arthropods, primarily insects like mosquitoes, ticks and flies. Some examples of vector-borne diseases include malaria, dengue and yellow fever. Antiparasitic drugs play an essential role in stopping the spread of vector-borne diseases by targeting and eliminating the parasites responsible. A few antiparasitic drugs, including chloroquine, doxycycline and atovaquone-proguanil, are commonly used to cure malaria. For instance, in August 2023, according to the Pan American Health Organization, a US-based specialized agency of the United Nations, dengue incidences had significantly increased in the US so far in 2023. More than 3 million new infections have been reported so far, exceeding the numbers for 2019-the year with the most significant recorded incidence of the disease in the area, with 3.1 million cases, including 28,203 severe cases and 1,823 deaths. Furthermore, in December 2022, according to the World Malaria Report 2022 published by the World Health Organization, a Switzerland-based intergovernmental organization, 247 million malaria cases were recorded worldwide in 2021, up from 245 million cases in 2020. Therefore, the increasing incidence of vector-borne diseases drives the growth of the antiparasitic drugs market.

Competitive Landscape -
Major players in the antiparasitic drugs market are Pfizer Inc., Johnson & Johnson, Cadila Pharmaceuticals, Merck & Co.Inc., Bayer AG, Novartis AG, Sanofi S.A., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim group, Zoetis Inc., Eisai Co. Ltd., Covetrus Inc., IDEXX Laboratories Inc., Dr. Reddy's Laboratories, Intas Pharmaceuticals Ltd., Alkem Laboratories Ltd., Ceva Sante Animale S.A., Elanco Animal Health Incorporated, Phibro Animal Health Corporation, Norbrook Laboratories Ltd., Mankind Pharma, Neogen Corporation, Bimeda Inc., Indoco Remedies Ltd., ECO Animal Health, Lincoln Pharmaceuticals Ltd., Laboratorios Calier.

US FDA Approval Marks A Milestone For Parapro's Natroba In The Antiparasitic Drugs Market
Major companies operating in the antiparasitic drugs market are focused on developing innovative products and solutions to sustain their position in the market. For instance, in August 2021, ParaPRO LLC, a US-based pharmaceutical company, launched Natroba Topical Suspension, the first antiparasitic product (new drug application) to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of scabies. Its active ingredient, Spinosad, acts on the lice's nervous system, causing paralysis and their demise. It is applied topically to the scalp and hair and may only require one application. Spinosad, the active ingredient in Natroba, is delivered to the stratum corneum, the outermost layer of the epidermis and targets mites at the site of infestation without penetrating deeply into the dermis or entering systemic circulation, which is what makes this therapeutic option unique.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/antiparasitic-drugs-global-market-report

Key Segments -
The antiparasitic drugs market covered in this report is segmented -
1) By Product Type: Anthelmintics; Antiprotozoals; Ectoparasiticide; Other Products
2) By Treatment: Avermectins; Bezimidazoles; Pyrimidines; Organophosphates; Imidazolesthiazoles
3) By Route of Administration: Oral; Injectable; Topical
4) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.